Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc Corporate Call Transcript

Nov 18, 2022 / 01:00PM GMT
Release Date Price: $6.62 (-6.76%)
Operator

Good day, and thank you for standing by. Welcome to the Iovance corporate update call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications. Please go ahead.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good morning, and thank you for joining our conference call to discuss the ongoing Biologics License Application, or BLA submission, for lifileucel, our new TIL therapy for patients with advanced melanoma. Earlier this morning, we issued a press release about the BLA submission that can also be found on our corporate website at iovance.com.

On today's call, Dr. Fred Vogt, our Interim President and Chief Executive Officer, will provide a brief introduction and summary. Then we will hold a question-and-answer session where several members of our executive leadership team are available to participate. Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot